MB02

DRUG2 trials

Sponsors

mAbxience Research S.L.

Conditions

Healthy VolunteersStage IIIB/IV Non-squamous Non-Small Cell Lung Cancer Lung Cancer

Phase 1

A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

CompletedNCT03293654

mAbxience Research S.L.Healthy Volunteers

Start: 2017-12-07End: 2019-05-29Updated: 2021-03-23

Phase 3

A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruitingLBCTR2018120171

mAbxience Research S.L.Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer Lung Cancer

Start: 2018-02-06Target: 576Updated: 2026-02-02

Related Papers

A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.

2021-07-169 citations

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).

2021-04-2923 citations